Acceder

Seguimiento de farmas para combatir el Covid-19

124 respuestas
Seguimiento de farmas para combatir el Covid-19
3 suscriptores
Seguimiento de farmas para combatir el Covid-19
Página
5 / 9
#61

Re: Seguimiento de farmas para combatir el Covid-19

ADMA Biologics, Inc. (ADMA)


  3.5168  +0.6768 (+23.831%)  A partir de las 11:36 AM EDT. Mercado abierto.

Rango del dia -3.2100 - 4.2000

Rango de 52 semanas 1.4500 - 5.4840  Volumen  28, 711 992
Media Volumen  2,778,136




#63

Re: Seguimiento de farmas para combatir el Covid-19

Qué miedo. Ojalá sea así o tendremos que alinearnos con los antivacunas :)

Nueva candidata que empezaría FI en septiembre y acabaría FIII en diciembre

http://www.globenewswire.com/news-release/2020/07/31/2071010/0/en/Sanofi-and-GSK-selected-for-Operation-Warp-Speed-to-supply-United-States-government-with-100-million-doses-of-COVID-19-vaccine.html

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#65

Re: Seguimiento de farmas para combatir el Covid-19

  Pricing Covid-19 vaccines too high could backfire on big pharmaceutical companies.
.
 I don’t want to single out Moderna here. It doesn’t have a single successful commercial drug, nor any other Phase 3 candidates; its need to make money off this vaccine is arguably acute. Larger drug companies are different. Yet Pfizer NSE 2.30% Inc.’s CEO recently said that calls for companies not to consider making a profit on their Covid-19 vaccines were “fanatic and radical.” (AstraZeneca NSE 1.51% PLC and Johnson & Johnson have promised a not-for-profit effort on their Covid-19 vaccines, 


 ..

#67

Re: Seguimiento de farmas para combatir el Covid-19

Para mi siguen siendo tulipanes, 
#68

Re: Seguimiento de farmas para combatir el Covid-19

#69

Re: Seguimiento de farmas para combatir el Covid-19

La probable futura del premio nobel de medicina Sarah Gilbert sacará millones de dosis de su vacuna para Septiembre y la comercializará Astrazeneca 
#70

Re: Seguimiento de farmas para combatir el Covid-19

 

Sorrento adds to COVID-19-stoked rally, shares up 24%

 
Aug. 10, 2020 1:56 PM ET|About: Sorrento Therapeutics,... (SRNE)|By: Douglas W. House, SA News Editor 
Sorrento Therapeutics (SRNE +23.6%) is adding to its recent breakout on almost double normal volume. Shares have jumped 159% since Wednesday, July 24, when it announced that it planned to acquire COVID-19 therapy developer SmartPharm Therapeutics. The following Monday, July 29, it announced that it in-licensed rights to a rapid test that detects the presence of the SARS-CoV-2 virus in saliva in as little as 30 minutes.

On Friday, May 15, shares rocketed 158% after the company announced a "cure" for COVID-19. Shares quickly retraced on questions about the veracity of its claim, bottoming at $3.82 on June 4. Investors appeared to have brushed off such concerns since shares are up five-fold since then.
Chairman, CEO and President Henry Li, Ph.D. is, no doubt, pleased with the share appreciation. Last week, the board authorized a 10-year performance award for him based solely on the market cap of the company. He will earn options to purchase up to ~24.9M shares at $17.30 representing a 10% stake in the company if fully exercised. The award vests in 10 equal tranches starting with ~2.5M options if the company's market cap reaches $5B. The 10th and last tranche vests if the company's value hits $35B. Assuming full vestment and no further equity offerings, his total award will be potentially worth ~$3.3B.

#71

Re: Seguimiento de farmas para combatir el Covid-19

Hola.
Que barbaridad, va como un cohete 
#73

Re: Seguimiento de farmas para combatir el Covid-19

Me fío poco o nada...
#74

Re: Seguimiento de farmas para combatir el Covid-19

A ver que laboratorio se lleva el premio gordo, apuesto por los anglosajones